Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Zentalis Pharmaceuticals Inc is a biotechnology business based in the US. Zentalis Pharmaceuticals shares (ZNTL) are listed on the NASDAQ and all prices are listed in US Dollars. Zentalis Pharmaceuticals employs 124 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$77.23|
|52-week range||$34.48 - $81.40|
|50-day moving average||$69.08|
|200-day moving average||$56.83|
|Wall St. target price||$81.78|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.50|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-0.89%|
|1 month (2021-09-21)||16.79%|
|3 months (2021-07-21)||52.66%|
|6 months (2021-04-21)||41.50%|
|1 year (2020-10-21)||90.41%|
|2 years (2019-10-17)||N/A|
|3 years (2018-10-17)||N/A|
|5 years (2016-10-17)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-41.69%|
|Return on equity TTM||-74.36%|
|Market capitalisation||$3.4 billion|
TTM: trailing 12 months
There are currently 2.5 million Zentalis Pharmaceuticals shares held short by investors – that's known as Zentalis Pharmaceuticals's "short interest". This figure is 8% up from 2.3 million last month.
There are a few different ways that this level of interest in shorting Zentalis Pharmaceuticals shares can be evaluated.
Zentalis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Zentalis Pharmaceuticals shares currently shorted divided by the average quantity of Zentalis Pharmaceuticals shares traded daily (recently around 303621.68087698). Zentalis Pharmaceuticals's SIR currently stands at 8.21. In other words for every 100,000 Zentalis Pharmaceuticals shares traded daily on the market, roughly 8210 shares are currently held short.
However Zentalis Pharmaceuticals's short interest can also be evaluated against the total number of Zentalis Pharmaceuticals shares, or, against the total number of tradable Zentalis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zentalis Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Zentalis Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.0795% of the tradable shares (for every 100,000 tradable Zentalis Pharmaceuticals shares, roughly 80 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Zentalis Pharmaceuticals.
Find out more about how you can short Zentalis Pharmaceuticals stock.
We're not expecting Zentalis Pharmaceuticals to pay a dividend over the next 12 months.
Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. The company also develops ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd. ; Pfizer, Inc. ; Eli Lilly and Company; and Zentera Therapeutics (Cayman), Ltd.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.